Tumor Subtype Determines Therapeutic Response to Chimeric Polypeptide Nanoparticle–based Chemotherapy in Pten-deleted Mouse Models of Sarcoma
Abstract
Nanoparticle-encapsulated drug formulations can improve responses to conventional chemotherapy by increasing drug retention within the tumor and by promoting a more effective antitumor immune response than free drug. New drug delivery modalities are needed in sarcomas because they are often chemoresistant cancers, but the rarity of sarcomas and the complexity of diverse subtypes makes it challenging to investigate novel drug formulations.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 15, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-2597
Entities
People
- Amanda Scherer
- Ashutosh Chilkoti
- David Kirsch
- Diana M Cardona
- Emily A Laverty
- Eric Mastria
- Gavin R McGivney
- Kathleen A. Ashcraft
- Mark Chen
- Parisa Yousefpour
- Rebecca D Dodd
- Soumen Saha
- Vickie Knepper-adrian
- Victoria R. Stephens
- Wade R Gutierrez
- Warren Floyd
- Wesley Huang
- William C. Eward
- Yan Ma
Organizations
- Congressionally Directed Medical Research Programs
- Duke University
- National Cancer Institute
- University of Iowa